Septerna Inc (SEPN)

Currency in USD
45.14
-3.05(-6.33%)
Closed·
45.30+0.16(+0.35%)
·
Advertisement
Unusual trading volume
SEPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
45.1048.95
52 wk Range
10.7451.10
Key Statistics
Prev. Close
48.19
Open
47.83
Day's Range
45.1-48.95
52 wk Range
10.74-51.1
Volume
877.88K
Average Volume (3m)
437.3K
1-Year Change
286.4726%
Book Value / Share
8.58
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SEPN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
51.00
Upside
+12.98%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Septerna Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 51.00
(+12.98% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Truist Securities
Buy59.00+30.70%43.00Maintain13/08/2026
H.C. Wainwright
Buy60.00+32.92%40.00Maintain12/08/2026
Wells Fargo
Buy50.00+10.77%48.00Maintain12/08/2026
Stifel
Buy49.00+8.55%43.00Maintain11/08/2026
Guggenheim
Buy51.00+12.98%45.00Maintain11/08/2026

Earnings

Latest Release
10/08/2026
EPS / Forecast
-0.29 / -0.74
Revenue / Forecast
26.75M / --
EPS Revisions
Last 90 days

Compare SEPN to Peers and Sector

Metrics to compare
SEPN
Peers
Sector
Relationship
P/E Ratio
−87.1x−10.1x−0.4x
PEG Ratio
−1.15−0.100.00
Price/Book
5.5x2.3x2.6x
Price / LTM Sales
21.3x11.5x3.1x
Upside (Analyst Target)
3.8%53.8%48.4%
Fair Value Upside
Unlock−11.0%6.5%Unlock

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.48M16.59%360.39M
Other Institutional Investors
58.14M83.41%2.80B
Public Companies & Retail Investors
0.000.00%0.00
Total
65.62M100.00%3.16B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Third Rock Ventures, LLC23.13%10,427,250502,489
RA Capital Management, L.P.15.52%6,995,858337,130

People Also Watch

193.90
SENEA
+2.94%
42.99
VIAV
-0.28%
2.2500
VGZ
-3.02%
337.82
ONTO
+0.14%
265.99
CRDO
-0.81%

FAQ

What Is the Septerna (NASDAQ: SEPN) Share Price Today?

The Septerna stock price today is 45.14 USD.

What Stock Exchange Does Septerna (SEPN) Trade On?

Septerna is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Septerna?

The stock symbol (also called a 'ticker') for Septerna is "SEPN."

What Is the Current Septerna Market Capitalisation?

As of today, Septerna (NASDAQ: SEPN) market cap is 2.11B USD.

What Is Septerna's (SEPN) Earnings Per Share (TTM)?

The Septerna EPS is currently -0.54 (Trailing Twelve Months).

When Is the Next Septerna Earnings Date?

Septerna's next earnings report will be released on 10/08/2026.

Is SEPN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Septerna moving averages and other technical indicators, the daily buy/sell signal for SEPN stock is Strong Buy.

How Many Times Has Septerna Stock Split?

Septerna has split 0 times. (See the SEPN stock split history page for full effective split date and price information.)

How Many Employees Does Septerna Have?

Septerna has 123 employees, based on their latest Companies House report.

What is the current trading status of Septerna (NASDAQ: SEPN)?

As of 14/08/2026, Septerna (SEPN) is trading at a share price of 45.14 USD, with a previous close of 48.19 USD. The stock has fluctuated within a day range of 45.10 USD to 48.95 USD, while its 52-week range spans from 10.74 USD to 51.10 USD.

What Is Septerna (SEPN) Price Target According to Analysts?

The average 12-month price target for Septerna is 51.00 USD, with a high estimate of 60 USD and a low estimate of 38 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +12.98% Upside potential.

What Is the SEPN Premarket Price?

SEPN's last pre-market stock price is 47.95 USD. The pre-market share volume is 200.00, and the stock has decreased by -0.24, or -0.50%.

What Is the SEPN After Hours Price?

SEPN's last after hours stock price is 45.30 USD, the stock has decreased by 0.16, or 0.35%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.